Department of Otorhinolaryngology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, UP, India.
Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi, UP, India.
Am J Trop Med Hyg. 2021 Dec 13;106(2):566-570. doi: 10.4269/ajtmh.21-0777.
There has been a surge of rhino-orbital mucormycosis cases in India in the wake of the second wave of the COVID-19 pandemic. It has been widely suggested that dysglycemia resulting from diabetes which is a common comorbidity in COVID-19 patients, and indiscriminate steroid use has resulted in this surge. We report a series of 13 cases of rhino-orbital mucormycosis in COVID-19 patients admitted to our center between mid-April and early June 2021. The cases showed a male preponderance, two patients had loss of vision, and four of them showed intracranial extension of disease. Twelve patients had received steroids and 12 had preexisting or newly diagnosed diabetes, both steroid use and diabetes being the most common identified risk factors. Considering other possible risk factors, immunosuppressed state, antiviral or ayurvedic (Indian traditional) medications, and oxygen therapy were not associated with a definite risk of mucormycosis, because they were not present uniformly in the patients. We propose that COVID-19 itself, through molecular mechanisms, predisposes to mucormycosis, with other factors such as dysglycemia or steroid use increasing the risk.
在第二波 COVID-19 大流行之后,印度的鼻眶脑毛霉菌病病例激增。人们普遍认为,糖尿病导致的血糖失调是 COVID-19 患者的常见合并症,而不规范使用类固醇则导致了这种激增。我们报告了 2021 年 4 月中旬至 6 月初期间我院收治的 13 例 COVID-19 患者的鼻眶脑毛霉菌病病例。这些病例显示出男性患病率较高,两名患者出现视力丧失,其中四人出现颅内疾病扩展。12 名患者使用过类固醇,12 名患者患有既往或新诊断的糖尿病,类固醇使用和糖尿病是最常见的确定风险因素。考虑到其他可能的风险因素,免疫抑制状态、抗病毒或阿育吠陀(印度传统)药物以及氧疗与毛霉菌病的明确风险无关,因为这些因素在患者中并非普遍存在。我们提出 COVID-19 本身通过分子机制使毛霉菌病易感性增加,而血糖失调或类固醇使用等其他因素则增加了风险。